EU/3/02/128

Table of contents

About

On 3 February 2003, orphan designation (EU/3/02/128) was granted by the European Commission to Enact Pharma plc, United Kingdom, for carboxypeptidase G2 for the adjunctive treatment in patients at risk of methotrexate toxicity.

The sponsorship was transferred to Protherics PLC, United Kingdom, in December 2004 and subsequently to Protherics Medicines Development Europe B.V., the Netherlands, in March 2020.

 

Key facts

Active substance
Carboxypeptidase G2
Disease / condition
Adjunctive treatment in patients at risk of methotrexate toxicity
Date of first decision
03/02/2003
Outcome
Positive
EU designation number
EU/3/02/128

Sponsor's contact details

Looskade 20
6041 LE Roermond
Limburg
Netherlands
Tel. +31 475 799 440
E-mail: pharma.regulatoryaffairs@btgplc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating